Review Article

CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease

Table 3

Studies of CD80 in minimal change disease that are support or against in both animals and humans.

Animal studiesStance on CD80Human studiesStance on CD80

Reiser et al., 2004 [24]SupportGarin et al., 2009 [22]Support
Shi et al., 2011 [149]SupportGarin et al., 2010 [100]Support
Ishimoto et al., 2013 [102]SupportIshimoto et al., 2013 [101]Support
Novelli et al., 2016 [20]AgainstYu et al., 2013 [23]Support
Rivard et al., 2018 [150]SupportCara-Fuentes et al., 2014 [26]Support
Khullar et al., 2018 [95]SupportNovelli et al., 2016 [20]Against
Mishra et al., 2017 [151]Support
Liao et al., 2017 [94]Support
Minamikawa et al., 2018 [152]Against
Zhao et al., 2018 [153]Support
Ling et al., 2018 [8]Support
Ahmed et al., 2018 [154]Support
Bhatia et al., 2018 [155]Support
Isom et al., 2019 [78]Support
Cara-Fuentes et al., 2020 [156]Support
Chen et al., 2020 [157]Support
Gonzalez et al., 2020 [158]Support